The role of PIM kinases in human and mouse CD4+ T cell activation and inflammatory bowel disease

Cellular Immunology

Volumn 272, Issue 2, 2012, Pages 200-213

  Jackson, Leila J ^a   Pheneger, Jed A ^a   Pheneger, Tracy J ^a   Davis, Gregg ^a   Wright, A Dale ^a   Robinson, John E ^a   Allen, Shelley ^a   Munson, Mark C ^a   Carter, Laura L ^a  

^a ARRAY BIOPHARMA INC   (United States)

Author keywords

Autoimmune; IBD; Inflammatory disease; P27; PIM; Proliferation; T cell

Indexed keywords

PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN KINASE PIM 1; PROTEIN KINASE PIM 3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL SURVIVAL; DISEASE MARKER; DISEASE SEVERITY; EFFECTOR CELL; ENTERITIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANIMALS; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CELL CYCLE CHECKPOINTS; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; CELL SURVIVAL; CYTOKINES; G0 PHASE; G1 PHASE; HUMANS; INFLAMMATORY BOWEL DISEASES; JANUS KINASES; LYMPHOCYTE ACTIVATION; MAP KINASE KINASE KINASES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, SCID; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-PIM-1; SIGNAL TRANSDUCTION;

EID: 83955165408     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2011.10.011     Document Type: Article

References (50)

1. Eichmann A., Yuan L., Breant C., Alitalo K., Koskinen P.J. Developmental expression of PIM kinases suggests functions also outside of the hematopoietic system. Oncogene 2000, 19:1215-1224.
2. Stout B.A., Bates M.E., Liu L.Y., Farrington N.N., Bertics P.J. IL-5 and granulocyte-macrophage colony-stimulating factor activate STAT3 and STAT5 and promote Pim-1 and cyclin D3 protein expression in human eosinophils. J. Immunol. 2004, 173:6409-6417.
3. Buckley A.R., Buckley D.J., Leff M.A., Hoover D.S., Magnuson N.S. Rapid induction of PIM-1 expression by prolactin and interleukin-2 in rat Nb2 lymphoma cells. Endocrinology 1995, 136:5252-5259.
4. Dautry F., Weil D., Yu J., Dautry-Varsat A. Regulation of PIM and myb mRNA accumulation by interleukin 2 and interleukin 3 in murine hematopoietic cell lines. J. Biol. Chem. 1988, 263:17615-17620.
5. Lilly M., Le T., Holland P., Hendrickson S.L. Sustained expression of the PIM-1 kinase is specifically induced in myeloid cells by cytokines whose receptors are structurally related. Oncogene 1992, 7:727-732.
6. Matikainen S., Sareneva T., Ronni T., Lehtonen A., Koskinen P.J., Julkunen I. Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and PIM-1 genes in human T cells. Blood 1999, 93:1980-1991.
7. Wingett D., Reeves R., Magnuson N.S. Stability changes in PIM-1 proto-oncogene mRNA after mitogen stimulation of normal lymphocytes. J. Immunol. 1991, 147:3653-3659.
8. Wang Z., Bhattacharya N., Weaver M., Petersen K., Meyer M., Gapter L., et al. Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J. Vet. Sci. 2001, 2:167-179.
9. Zhu N., Ramirez L.M., Lee R.L., Magnuson N.S., Bishop G.A., Gold M.R. CD40 signaling in B cells regulates the expression of the Pim-1 kinase via the NF-kappa B pathway. J. Immunol. 2002, 168:744-754.
10. Fox C.J., Hammerman P.S., Thompson C.B. The Pim kinases control rapamycin-resistant T cell survival and activation. J. Exp. Med. 2005, 201:259-266.
11. Amson R., Sigaux F., Przedborski S., Flandrin G., Givol D., Telerman A. The human protooncogene product p33PIM is expressed during fetal hematopoiesis and in diverse leukemias. Proc. Natl. Acad. Sci. USA 1989, 86:8857-8861.
12. Valdman A., Fang X., Pang S.T., Ekman P., Egevad L. Pim-1 expression in prostatic intraepithelial neoplasia and human prostate cancer. Prostate 2004, 60:367-371.
13. Cibull T.L., Jones T.D., Li L., Eble J.N., Ann Baldridge L., Malott S.R., et al. Overexpression of Pim-1 during progression of prostatic adenocarcinoma. J. Clin. Pathol. 2006, 59:285-288.
14. van Lohuizen M., Verbeek S., Krimpenfort P., Domen J., Saris C., Radaszkiewicz T., et al. Predisposition to lymphomagenesis in PIM-1 transgenic mice. cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell 1989, 56:673-682.
15. Allen J.D., Verhoeven E., Domen J., van der Valk M., Berns A. Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc. Oncogene 1997, 15:1133-1141.
16. Didichenko S.A., Spiegl N., Brunner T., Dahinden C.A. IL-3 induces a Pim1-dependent antiapoptotic pathway in primary human basophils. Blood 2008, 112:3949-3958.
17. Andina N., Didichenko S., Schmidt-Mende J., Dahinden C.A., Simon H.U. Proviral integration site for Moloney murine leukemia virus 1, but not phosphatidylinositol-3 kinase, is essential in the antiapoptotic signaling cascade initiated by IL-5 in eosinophils. J. Allergy Clin. Immunol. 2009, 123:603-611.
18. Leduc I., Karsunky H., Mathieu N., Schmidt T., Verthuy C., Ferrier P., et al. The Pim-1 kinase stimulates maturation of TCRbeta-deficient T cell progenitors: implications for the mechanism of Pim-1 action. Int. Immunol. 2000, 12:1389-1396.
19. Jacobs H., Krimpenfort P., Haks M., Allen J., Blom B., Demolliere C., et al. PIM1 reconstitutes thymus cellularity in interleukin 7- and common gamma chain-mutant mice and permits thymocyte maturation in Rag- but not CD3gamma-deficient mice. J. Exp. Med. 1999, 190:1059-1068.
20. Schmidt T., Karsunky H., Rodel B., Zevnik B., Elsasser H.P., Moroy T. Evidence implicating Gfi-1 and Pim-1 in pre-T-cell differentiation steps associated with beta-selection. EMBO J. 1998, 17:5349-5359.
21. Mikkers H., Nawijn M., Allen J., Brouwers C., Verhoeven E., Jonkers J., et al. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol. Cell. Biol. 2004, 24:6104-6115.
22. Powrie F. Induction of Inflammatory Bowel Disease in Immunodeficient Mice by Depletion of Regulatory T cells 2001, John Wiley and Sons, Inc.
23. Rainio E.M., Sandholm J., Koskinen P.J. Cutting edge: transcriptional activity of NFATc1 is enhanced by the Pim-1 kinase. J. Immunol. 2002, 168:1524-1527.
24. Rohwer F., Todd S., McGuire K.L. The effect of IL-2 treatment on transcriptional attenuation in proto-oncogenes PIM-1 and c-myb in human thymic blast cells. J. Immunol. 1996, 157:643-649.
25. Testa U., Kuhn L., Petrini M., Quaranta M.T., Pelosi E., Peschle C. Differential regulation of iron regulatory element-binding protein(s) in cell extracts of activated lymphocytes versus monocytes-macrophages. J. Biol. Chem. 1991, 266:13925-13930.
26. Tamas P., Macintyre A., Finlay D., Clarke R., Feijoo-Carnero C., Ashworth A., et al. LKB1 is essential for the proliferation of T-cell progenitors and mature peripheral T cells. Eur. J. Immunol. 2010, 40:242-253.
27. Morishita D., Katayama R., Sekimizu K., Tsuruo T., Fujita N. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res. 2008, 68:5076-5085.
28. Zhang Y., Wang Z., Magnuson N.S. Pim-1 kinase-dependent phosphorylation of p21Cip1/WAF1 regulates its stability and cellular localization in H1299 cells. Mol. Cancer Res. 2007, 5:909-922.
29. Wang Z., Bhattacharya N., Mixter P.F., Wei W., Sedivy J., Magnuson N.S. Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim. Biophys. Acta 2002, 1593:45-55.
30. Leach M.W., Bean A.G., Mauze S., Coffman R.L., Powrie F. Inflammatory bowel disease in C.B-17 SCID mice reconstituted with the CD45RBhigh subset of CD4+ T cells. Am. J. Pathol. 1996, 148:1503-1515.
31. Bachmann M., Moroy T. The serine/threonine kinase Pim-1. Int. J. Biochem. Cell Biol. 2005, 37:726-730.
32. Paukku K., Silvennoinen O. STATs as critical mediators of signal transduction and transcription: lessons learned from STAT5. Cytokine Growth Factor Rev. 2004, 15:435-455.
33. Wingett D., Long A., Kelleher D., Magnuson N.S. Pim-1 proto-oncogene expression in anti-CD3-mediated T cell activation is associated with protein kinase C activation and is independent of Raf-1. J. Immunol. 1996, 156:549-557.
34. Peperzak V., Veraar E.A., Keller A.M., Xiao Y., Borst J. The Pim Kinase Pathway Contributes to Survival Signaling in Primed CD8+ T Cells upon CD27 Costimulation. J. Immunol. 2010, 185:6670-6678.
35. Kwon T.K., Buchholz M.A., Ponsalle P., Chrest F.J., Nordin A.A. The regulation of p27Kip1 expression following the polyclonal activation of murine G0 T cells. J. Immunol. 1997, 158:5642-5648.
36. Boonen G.J., van Dijk A.M., Verdonck L.F., van Lier R.A., Rijksen G., Medema R.H. CD28 induces cell cycle progression by IL-2-independent down-regulation of p27kip1 expression in human peripheral T lymphocytes. Eur. J. Immunol. 1999, 29:789-798.
37. Appleman L.J., van Puijenbroek A.A., Shu K.M., Nadler L.M., Boussiotis V.A. CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells. J. Immunol. 2002, 168:2729-2736.
38. Wells A.D., Walsh M.C., Sankaran D., Turka L.A. T cell effector function and anergy avoidance are quantitatively linked to cell division. J. Immunol. 2000, 165:2432-2443.
39. Greenwald R.J., Boussiotis V.A., Lorsbach R.B., Abbas A.K., Sharpe A.H. CTLA-4 regulates induction of anergy in vivo. Immunity 2001, 14:145-155.
40. Kubsch S., Graulich E., Knop J., Steinbrink K. Suppressor activity of anergic T cells induced by IL-10-treated human dendritic cells: association with IL-2- and CTLA-4-dependent G1 arrest of the cell cycle regulated by p27Kip1. Eur. J. Immunol. 2003, 33:1988-1997.
41. Rowell E.A., Wang L., Hancock W.W., Wells A.D. The cyclin-dependent kinase inhibitor p27kip1 is required for transplantation tolerance induced by costimulatory blockade. J. Immunol. 2006, 177:5169-5176.
42. Rudd C.E. Cell cycle 'check points' T cell anergy. Nat. Immunol. 2006, 7:1130-1132.
43. Li L., Iwamoto Y., Berezovskaya A., Boussiotis V.A. A pathway regulated by cell cycle inhibitor p27Kip1 and checkpoint inhibitor Smad3 is involved in the induction of T cell tolerance. Nat. Immunol. 2006, 7:1157-1165.
44. Ohnuki K., Watanabe Y., Takahashi Y., Kobayashi S., Watanabe S., Ogawa S., et al. Antigen-specific CD4+ effector T cells: analysis of factors regulating clonal expansion and cytokine production: clonal expansion and cytokine production by CD4+ effector T cells. Biochem. Biophys. Res. Commun. 2009, 380:742-747.
45. Monteleone G., Caprioli F. T-cell-directed therapies in inflammatory bowel diseases. Clin. Sci. (Lond.) 2010, 118:707-715.
46. Feagan B.G., Greenberg G.R., Wild G., Fedorak R.N., Pare P., McDonald J.W., et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N. Engl. J. Med. 2005, 352:2499-2507.
47. Timmer A., McDonald J.W., Macdonald J.K. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev. 2007, CD000478.
48. Sandborn W.J., Colombel J.F., Enns R., Feagan B.G., Hanauer S.B., Lawrance I.C., et al. Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 2005, 353:1912-1925.
49. Sandborn W., Sutherland L., Pearson D., May G., Modigliani R., Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst. Rev. 2000, CD000545.
50. Targan S.R., Feagan B.G., Fedorak R.N., Lashner B.A., Panaccione R., Present D.H., et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007, 132:1672-1683.